Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation Of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of US dollars ($)	Three Months Ended March 31, 2020
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	199	$	199	$	—
License Fee – Over time	56		—		56
Total Drug Products	255		199		56
Concentrate Products
Product Sales – Point-in-time	15,112		13,506		1,606
License Fee – Over time	490		490		—
Total Concentrate Products	15,602		13,996		1,606
Net Revenue	$	15,857	$	14,195	$	1,662

	Three Months Ended March 31, 2019
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	68	$	—	68
Total Drug Products	68		—		68
Concentrate Products
Product Sales – Point-in-time	14,996		12,923		2,073
License Fee – Over time	495		495		—
Total Concentrate Products	15,491		13,418		2,073
Net Revenue	$	15,559	$	13,418	$	2,141

Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands of US dollars ($)	March 31, 2020		December 31, 2019
Receivables, which are included in "Trade and other receivables"	$	4,587	$	4,203
Contract liabilities	$	11,630	$	12,076